Description
Ibandronic Acid Injections 1 mg/ml. 3 ml. Vial №1
Ingredients
Each 3 ml vial contains 3 mg of Ibandronic Acid.
Mechanism of Action
Ibandronic Acid is a bisphosphonate that acts by inhibiting bone resorption through the suppression of osteoclast activity, thereby increasing bone mineral density and reducing the risk of fractures.
Pharmacological Properties
Ibandronic Acid, a potent bisphosphonate, exerts its effects by specifically targeting osteoclast-mediated bone resorption, leading to improved bone strength and reduced fracture susceptibility.
Indications for Use
Ibandronic Acid Injections are indicated for the treatment and prevention of osteoporosis in postmenopausal women to enhance bone density and reduce the risk of fractures associated with osteoporosis.
Contraindications
Do not administer Ibandronic Acid Injections in cases of hypocalcemia or in individuals with a known hypersensitivity to bisphosphonates due to the potential for adverse reactions.
Side Effects
Common side effects of Ibandronic Acid Injections may include gastrointestinal disturbances, musculoskeletal pain, and flu-like symptoms. Rare but severe adverse effects may include osteonecrosis of the jaw or atypical femoral fractures.
Usage Instructions
The recommended dosage of Ibandronic Acid is 1 mg/ml to be administered as a slow intravenous injection over a minimum of 15 seconds once every 3 months under the supervision of a qualified healthcare provider.
Benefits Compared to Analogues
Studies have shown that Ibandronic Acid is comparable in efficacy to other bisphosphonates in reducing fracture risk and improving bone health in postmenopausal women, with the added benefit of a less frequent dosing regimen.
Suitable Patient Groups
Ibandronic Acid Injections are suitable for postmenopausal women at risk of or diagnosed with osteoporosis, including elderly patients and those unable to tolerate oral bisphosphonates.
Storage and Shelf Life
Store Ibandronic Acid Injections as per the manufacturer’s instructions, typically at room temperature away from light and moisture. Check the expiry date on the packaging and do not use expired products.
Packaging Description
Ibandronic Acid Injections are supplied in 3 ml vials containing 1 mg/ml of the active ingredient, each vial is for single-use only and should be discarded properly after administration.
Clinical Evidence and Proven Effectiveness
Research published in the Journal of Bone and Mineral Research has demonstrated the efficacy of Ibandronic Acid in reducing the risk of vertebral fractures in postmenopausal women with osteoporosis. Clinical trials have shown significant improvements in bone mineral density and fracture prevention with the use of Ibandronic Acid.
